Annotation Detail

Information
Associated Genes
AR
Associated Variants
AR OVEREXPRESSION ( ENST00000374690.9 )
AR OVEREXPRESSION ( ENST00000374690.9 )
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroduction of AR expression resensitized nonresponsive AR-negative cells to NVP-BEZ235. A dihydrotestosterone (DHT) and NVP-BEZ235 combination achieved tumor regression and complete response in AR/ER expressing tumors (xenografts).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/859
Gene URL
https://civic.genome.wustl.edu/links/genes/67
Variant URL
https://civic.genome.wustl.edu/links/variants/359
Rating
3
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Supports
Drug
Dactolisib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
24356815
Drugs
Drug NameSensitivitySupported
DactolisibSensitivitytrue